drugset
drugset / Trial / NCT02259933

Safety, Tolerability and Pharmacokinetics of KUC 7483 CL Tablets in Healthy Male Volunteers

NCT02259933 ↗

Phase 1 Completed 35 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate safety, tolerability and pharmacokinetics of KUC 7483 CL after repeated dosing

Timeline

Start
2004-02
Primary completion
2004-05
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject KUC 7483 CL Unknown 40 mg Oral
Subject KUC 7483 CL Unknown 120 mg Oral
Subject KUC 7483 CL Unknown 180 mg Oral

Indications

No indication recorded.